Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by PoorOpinionon Dec 06, 2018 2:18am
169 Views
Post# 29073873

public payors

public payorsWhat's the situation atm with gov payors? Do we know if many patients are getting treatment through gov schemes yet?
I ask because I thought this recent article had some interesting things to say about Trogarzo. Even if it is just talking about the jailed population it shows the general thinking on the drug.

https://www.feldesmantucker.com/ryan-white-hiv-aids-program-update/

https://hab.hrsa.gov/sites/default/files/hab/program-grants-management/PolicyADAPOct2018DearColleagueLetter-508.pdf

I had thought that trogarzo was being classed with other attachment inhibitors. I thought TH/taimed had tried, and failed, to get it classed separately with the FDA.  But it looks like within the public sphere it is getting separate class status, that's important because ADAPs are obliged to offer at least one of each class of drug so Trogarzo goes on every formulary.

 Am I just late to the party? Is this already known?


Bullboard Posts